Cdk14 - cyclin-dependent kinase 14 Gene
Also Known as Pftk1
Species: Rattus norvegicus
About Cdk14
This gene has 3 transcripts (splice variants), 201 orthologues, 24 paralogues and is associated with 2 phenotypes. Biased expression in Brain (RPKM 211.8), Lung (RPKM 2.1) and 9 other tissues.
Summary
Predicted to enable cyclin binding activity and cyclin-dependent protein serine/threonine kinase activity. Predicted to be involved in mitotic cell cycle phase transition; protein phosphorylation; and regulation of canonical Wnt signaling pathway. Predicted to be located in nucleoplasm and plasma membrane. Predicted to be part of cytoplasmic cyclin-dependent protein kinase holoenzyme complex. Predicted to be active in cytosol and nucleus. Orthologous to human CDK14 (cyclin dependent kinase 14). [provided by Alliance of Genome Resources, Apr 2022]
Cdk14 Products (3)
| mRNA | Protein | Name |
|---|---|---|
| NM_001395583.1 | NP_001382512.1 | cyclin-dependent kinase 14 isoform 1 |
| NM_001395582.1 | NP_001382511.1 | cyclin-dependent kinase 14 isoform 1 |
| NM_001395584.1 | NP_001382513.1 | cyclin-dependent kinase 14 isoform 2 |
Cdk14 Protein Structure
STKc_PFTAIRE1: cd07869 (128 - 430)
- 0
- 100
- 200
- 300
- 400
- 469 a.a.
| Protein Preferred Names | Protein Names | |
|---|---|---|
|
cyclin-dependent kinase 14 |
|
Related Agents
- Clinical Phase
- Pre-clinical Phase
Clinical Phase
| Cat. No. | Product Name |
Effect
|
Purity |
Phase
|
|---|---|---|---|---|
| HY-X0009 | Tambiciclib | Inhibitor | 99.68% | Phase 2 |
Pre-clinical Phase
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-127104 | FMF-04-159-2 | Inhibitor | 99.64% | Unkown |
| HY-X0150 | JSH-150 | Inhibitor | 98.36% | Unkown |
| HY-137342 | SB1-G-187 | Degrader | 98.70% | Unkown |
| HY-X0009A | Tambiciclib dimaleate | Inhibitor | 99.53% | Unkown |
| HY-160213 | JA397 | Inhibitor | / | Unkown |
Compound Screening Libraries
Virtual Screening
Customize Your Library
Drug Screening Service